 |
Scottsdale, Arizona., September 10, 2025 /PRNewswire/ – Imaging Endpoint (IE) is a global leader in imaging CRO technology and services for oncology testing and has announced the filing of a provisional patent application for its innovative AI-enhanced Imaging Review Charter (IRC) system. This innovative Airc System™ is designed to enhance highly customized IRC for clinical trials, setting new standards in the industry.
Imaging Endpoint announces patent application for AIRC System™
Imaging endpoints are the scientific leader in customizing and optimizing image acquisition and optimization for clinical trials in oncology, and are the industry's most sophisticated approach to ensuring clarification and/or modification of published criteria to enhance each unique clinical trial design. This sophisticated approach to image analysis contributes to the company's outstanding 95% marketing approval success rate, which supports over 200 regulatory approvals.
The new AIRC system addresses longstanding challenges in testing imaging design by ensuring the alignment of current regulatory requirements of FDAs, EMAs and other regulatory bodies around the world, while helping Intelligent, Taulared Modification and/or Clarification assimilate data to standard oncology standards.
Key features of the new AIRC system:
- Dynamic Customization: The system includes customization modules that integrate datasets from industry standards, published oncology criteria, analysis libraries of imaging endpoints, and trial information from research protocols and experimental agents (such as mechanisms of action) to generate dynamic IRC documents.
- Optimizing the criteria: The system provides the largest dataset and key methods for identifying the specific criteria needed to optimize image acquisition and analysis of each unique trial.
- Strengthened regulatory compliance: While globally integrating FDA and other regulatory agencies' requirements, standards, guidelines, and recent industry-wide findings to more clearly explain standards strengthening, the AIRC system helps optimize compliance with regulatory standards while improving the efficiency of sponsor and agency reviews.
- Improved efficiency: The system utilizes AI to compile and integrate data applied to IE physicians, science, operational and regulatory experts to evaluate faster test setups with reliable results.
Doug Dean BurkettCEO and president of Imaging Endpoint commented on the innovation. Connect the imaging to Cure™. This AI will further strengthen industry leadership while strengthening the IRC system and increasing the efficiency and effectiveness of oncology testing. ”
For more information or copying the criteria optimization in recent white papers of images, see Optimizing Imaging Response Criteria for Improved Results of Oncology Clinical Trials.
About Imaging Endpoints
Imaging endpoints (i.e.) are passionately focused on the vision of connecting imaging to treatment. With a perfect global inspection record and an astounding 95% success rate of marketing approval, IE has a proven track record in supporting successful regulatory submissions around the world. IE's commitment to quality, innovation, rapid turnover times and operational excellence has positioned it as a global leader in tumor imaging.
The imaging endpoint is the largest oncology imaging CRO, with eight offices strategically located in six countries. ScottsdaleAZ, Cambridge, MA. London, UK;Leiden, Netherlands; Basel, Switzerland; Hyderabad, India;and Shanghai, China.
IE is an affiliate of HonorHealth, one of the nation's largest healthcare systems, and Southwest Medical Imaging, Ltd, which is part of the largest private radiology group in the United States. It is part of (Smil/Radpartners).
For other media queries, please contact us. [email protected] |Please contact us. +1 480.314.3070.
